For example, Guttman-Yassky et al. recently demonstrated that dupilumab treatment does significantly improve type 2 inflammatory signatures (IL-13, IL-31, CCL17, CCL18, and CCL26) in the blood and cutaneous tissues.[9] Our previous studies also demonstrated that periostin and SCCA2 are downstream molecules of IL-4/IL-13 signaling and that these molecules are highly expressed in inflamed sites of AD patients.[48–50] However, none of them has been analyzed as a predictor of response to dupilumab treatment. This evidence concerns the gene CCL26 and Alzheimer disease.